Nasdaq GlobeNewswire

3D Signatures Inc. and l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView(TM) with Genome Sequence Analysis in Lung Cancer

Del

3D Signatures Inc. / 3D Signatures Inc. and l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView(TM) with Genome Sequence Analysis in Lung Cancer . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, is pleased to announce that it has signed a collaboration agreement with l'Institut Universitaire de Cardiologie et de Pneumologie de Québec ("IUCPQ") to evaluate the clinical application of 3DS' proprietary TeloView(TM) software platform alongside DNA sequence analysis in lung cancer.

The study will be conducted at 3DS' laboratory in Toronto, Canada, through a collaboration with Dr. Philippe Joubert (MD, PhD, FRCPC), anatomic pathologist at the IUCPQ, researcher at the IUCPQ Research Center, and assistant clinical professor in the Department of Molecular Biology, Medical Biochemistry, and Pathology at Laval University. IUCPQ will conduct whole exome sequence analysis, and provide 3DS with matching tissue samples from the IUCPQ Tumor Bank, from patients with non-small cell lung cancer (NSCLC).

"Pathologists have a variety of emerging technologies available that may offer new insights into optimal disease management", states Dr. Joubert. "This pilot is an exciting opportunity to evaluate how three-dimensional telomere analysis may complement other new tools at our disposal to offer potential benefits to healthcare providers, lung cancer patients, and the healthcare system".

According to the World Health Organization, lung cancer is the most common cancer in the world, accounting for over 1.8 million new cases annually, and remains the leading cause of cancer deaths each year.1 Targeted therapies against specific gene mutations have had an important but limited effect on the total lung cancer population. The recent introduction of immunotherapies has been highly effective in only a minority of patients because clinicians lack robust biomarkers to predict which patients will benefit from these expensive treatments.

"We look forward to this additional collaboration with Dr. Joubert and the IUCPQ, to further expand TeloView's potential application as a universal clinical biomarker in cancer," commented Jason Flowerday, CEO of 3DS. "We hope this pilot study will be an important precedent for demonstrating how our TeloView(TM) platform may integrate with genomic sequencing with the aim of supporting clinical decisions for the precision care of such a large patient population as lung cancer."

About the IUCPQ

Since its creation in 1918, the Institut Universitaire De Cardiologie et de Pneumologie de Quebec has stood on equal footing with leading North American establishments for ultra-specialized care. Specializing in the health of persons with cardiopulmonary diseases, the Institute is renowned and recognized internationally as a leader. What distinguishes the Institute is its expertise and innovative practices, its focus on research and teaching, and its technological advances. The Institute is where specialized expertise and the sharing of knowledge come together in an ongoing quest for excellence. The close and continuing synergy between clinical activities, research, teaching and the evaluation of health technologies and interventions ensures a care approach guided by best practices and forms the cornerstone of the Institute's mission.

About the IUCPQ Research Center

The Québec Heart and Lung Institute (IUCPQ) Research Centre is the only centre funded by the Fonds de recherche du Québec - Santé (FRQS) that regroups three research components (cardiology, respirology and obesity-metabolism) deemed to be a priority because of the considerable economic and social impact of their related diseases. Our centre is unique in that our research components perfectly complement the Institute's clinical missions. This enables health professionals and researchers to work in total synergy to the greatest benefit of patients. Since 2000, the personnel went from 268 to 906 employees, including 171 principal investigators. 

For more information, visit the Institute's website: http://iucpq.qc.ca/en

The information concerning IUCPQ contained in this news release has been provided by IUCPQ. Although 3DS has no knowledge that would indicate that any statements contained herein concerning IUCPQ are untrue and incomplete, the directors and officers of 3DS assume no responsibility for the accuracy and completeness for such information.

About 3DS

3DS (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0)  is a personalized medicine company with a proprietary software platform, TeloView(TM), that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS' TeloView(TM) software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug's efficacy and toxicity. 3DS' proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloView(TM) platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual's disease based on their unique TeloView Score(TM). As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloView(TM) platform to deliver personalized medicine that allows for better treatments, leading to better outcomes.

The TeloView(TM) platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer's disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin's lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS' intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease.

For more information, visit the Company's website at: http://www.3dsignatures.com.

For further information, please contact:

Jason Flowerday
CEO & Director
416-673-8487
investors@3dsignatures.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward looking statements which constitute "forward looking information" within the meaning of applicable Canadian securities legislation ("Forward-Looking Statements").  All statements included herein, other than statements of historical fact, are Forward-Looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward-Looking Statements. Often, but not always, these Forward-Looking Statements can be identified by the use of words such as "estimates", "potential", "open", "future", "assumes", "projects", "anticipates", "believes", "may", "continues", "expects", "plans", "will", "to be", or statements that events "could" or "should" occur or be achieved, and similar expressions, including negative variations. Statements with respect to 3DS' collaboration with IUCPQ and the study's ability to build on previous evidence in respect of 3DS' TeloViewTM software platform, among others, are Forward-Looking statements.

Such Forward-Looking Statements reflect the Company's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by 3DS as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many risk factors could cause the Company's actual results, performance, achievements, prospects or opportunities to be materially different from any future results, performance or achievements that may be expressed or implied by such Forward Looking Statements, including risks related to the failure of 3DS and IUCPQ to execute successfully on the collaboration agreement or at all; the risk that the Telo-HLTM test may not be commercially launched as an LDT or for research use by the first quarter of 2018, or at all; uncertainties related to 3DS' clinical trials and test development; risks related to the volatility of the price of 3DS' common shares; risks related to the possibility that 3DS' shareholders may experience dilution; risks related to 3DS' requirements for additional financing and future access to capital, including the risk that the proceeds raised under the Private Placement may be insufficient to finance 3DS' business objectives; the risk that a positive return on an investment in 3DS' common shares is not guaranteed; risks related to 3DS' intention to retain earnings and not pay cash dividends on its common shares in the foreseeable future; risks related to 3DS' early stage of development; the risk that 3DS' tests will not be successfully deployed; risks related to 3DS' dependence on third parties, including collaborative partners, licensors and others; risks related to 3DS' clinical trial recruitment; that there is currently no market for 3DS' products and that such market may be slow to develop if at all; risks related to 3DS' reliance on key personnel; risks related to the competitive nature of the biotechnology industry; risks related to 3DS' limited operating history, lack of revenue, history of losses and inability to assure that it will earn profits in the future or that profitability will be sustained; risks related to government regulation; risks related to rapid technological change; risks related to the fact that 3DS' software may now or in the future contain undetected errors, bugs or vulnerabilities; the risk that 3DS or its directors and officers may be subject to a variety of civil or other legal proceedings, with or without merit, including product liability claims; risks related to the protection of 3DS' intellectual property rights; risks related to 3DS' limited sales, marketing and distribution experience; risks related to the possibility that 3DS' directors and officers may be placed in a conflict of interest as a result of their employment or affiliation with third parties, risks related to 3DS' use and storage of personal information and compliance with applicable privacy laws, as well as those risks discussed under the heading "Risk Factors" in the Company's annual management's discussion and analysis dated October 23, 2017 and filed on SEDAR. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the Forward-Looking Statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

In making the Forward-Looking Statements, the Company has made various material assumptions including, but not limited to, that 3DS and IUCPQ will collaborate successfully, obtaining positive results from 3DS' current and planned clinical trials and research and development initiatives; including the study with IUCPQ; that the Telo-HLTM test will be commercially launched as an LDT or for research use by the first quarter of 2018; obtaining regulatory approvals with respect to 3DS' clinical trials which are now ongoing or may in the future be commenced; 3DS' ability to successfully develop its tests; assumptions regarding general business and economic conditions; that 3DS' current positive relationship with third parties will be maintained; the availability of future financing on reasonable terms; 3DS' ability to attract and retain skilled staff; assumptions regarding market competition and the products and technology offered by 3DS' competitors; and 3DS' ability to protect patents and proprietary rights.

3DS believes that the assumptions and expectations reflected in the Forward-Looking Statements in this press release are reasonable, but no assurance can be given that these expectations will prove to be correct. Forward-Looking Statements should not be unduly relied upon. This information speaks only as of the date of this press release, and 3DS will not necessarily update this information, unless required to do so by securities laws.  

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

  1. http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp 

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 3D Signatures Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Williams Scotsman to Acquire ModSpace22.6.2018 13:09Pressemelding

Creates an industry-leading specialty rental services provider with over $1 billion of combined revenue and over 160,000 rental units across North America Leverages, and further strengthens, Williams Scotsman's scalable operating platform to capture an estimated $60 million of cost synergies Combines the best of both companies' go-to-market strategies, benefiting our customers and accelerating the expansion of Williams Scotsman's turnkey "Ready To Work" solutions across a broader asset base and enhanced branch network Total enterprise value of approximately $1.1 billion represents 6.6x ModSpace's Adjusted EBITDA for the twelve month period ended March 31, 2018, inclusive of forecast cost synergies and the expected value of acquired tax attributes1 ,2 BALTIMORE, June 22, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman") the leading specialty rental services provider of innovative modular space and portable storage solutions across North America, today anno

Mash named as one of the Fintech 5022.6.2018 12:36Pressemelding

At an event held on Wednesday June 20th at the Silicon Valley Bank in London, UK, Mash was selected from over 1800 companies to the FinTech50 2018 list, joining FinTech giants like N26, Monzo, Raisin and Revolut on the list of Europe’s hottest FinTech companies. James Hickson, Group CEO of Mash commented, “This has been a transformational year for Mash and our momentum continues. The FinTech50 is the Oscars of our industry and as such, the competition for a place was incredibly high - only 14 new companies made it to the list with Mash being selected from over 1800 nominations. To be recognized as one of Europe’s leading Fintech companies is an incredible honor and a reflection of our dedicated team and our go forward ambition to be a major player in Europe. We extend an enormous thank you to the award committee for their support and our team for their incredible efforts” Tommi Lindfors, Chairman and founder of Mash Group, was pleased with the recognition: “The Fintech50 list recognize

GMAC Launches 'Study in China' Initiative in Partnership with 11 Leading Business Schools in China22.6.2018 06:01Pressemelding

BEIJING and HONG KONG, June 22, 2018 (GLOBE NEWSWIRE) -- On June 22, the Graduate Management Admission Council (GMAC) joins hands with 11 leading business schools in China to launch the "Study in China" initiative. This partnership marks the opening of an interactive platform for international students across 20 Belt and Road (B&R) regions to explore opportunities in China and to pursue higher education in business-related fields. The "Study in China" initiative aims to meet rapidly growing international student demand and to champion China as a world-class study destination and emerging global hub for business education. The "Study in China" online portal (www.studyinchinamba.com) officially launched today allows students to discover more about studying and living in China. The newly designed English-language website connects prospective students with partner business schools and offers access to an abundance of information to help find the perfect fit for their China education experi

Minimize the Impact of an Infrastructure Disaster with Integrated Asset Planning and Optimization21.6.2018 20:37Pressemelding

ATLANTA, June 21, 2018 (GLOBE NEWSWIRE) -- PowerPlan, a leader in asset investment optimization software, has released a new white paper titled, "Are you prepared to stop a large infrastructure disaster from also becoming a financial disaster?" The white paper highlights the impact of limited capital on infrastructure disaster relief, and offers solutions to minimize the impact with holistic asset plans. Sourcing the American Society of Civil Engineers, the paper states that the infrastructure in the United States has been rated a D+, showing no improvement from 2013. "All organizations hope that they can avoid asset failures from happening to their infrastructure. However, most don't have solutions in place that enable them to effectively plan their asset investment needs to prevent those failures," said Dillon Blakes, Senior Product Manager at PowerPlan. "With this paper, we hope to help educate asset intensive organizations, like those in the public sector, utilities, oil and gas, e

Shyft Unveils Board of Advisors Comprised of Top Crypto, Industry, and Regulatory Leaders United to Redefine Identity, Regulatory Compliance and Privacy For All21.6.2018 20:18Pressemelding

St. Michael, Barbados, June 21, 2018 (GLOBE NEWSWIRE) -- Shyft, a leading blockchain-based solution that is building a trusted ecosystem to enable secure and private data transfers, has announced its high profile Board of Advisors. Shyft's inaugural group of advisors bring deep industry knowledge from international business and finance, blockchain, economics, and Know Your Customer (KYC) and Anti Money Laundering (AML) compliance. The Board of Advisors will play a critical role in providing strategic guidance across multiple dimensions in Shyft's mission to make the global economy more efficient and effectively regulated. Shyft International Chairman Joseph Weinberg says: "At Shyft, we are ambitiously working to redefine the broken way our world uses and thinks about data, the same data that today defines our identity. Our group of advisors understand the dire need for a new system that allows attested data to not only be shared securely and privately, but also a system that can help b

United Shore Selects VITEC's EZ TV IPTV & Digital Signage Platform for New Headquarters21.6.2018 19:00Pressemelding

SUNNYVALE, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced that it has been chosen by United Shore to provide high-definition (HD), ultra-low-latency IP streaming and digital signage capabilities throughout the mortgage lender's new corporate headquarters in Pontiac, Michigan. Designed to seamlessly integrate with any IT environment and run on LAN, WAN, or wireless networks, the EZ TV Platform will provide United Shore with a secure, scalable, and cost-effective way to distribute a comprehensive lineup of TV channels and signage to more than 150 displays around the company's new 600,000-square-foot building over its IP infrastructure, and without the cost of installing RF cabling. Providing its more than 2,400 employees with valuable company information and essential television content, the new EZ TV Platform will be part of the company's initiative to create a dynamic and collaborative work environ

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom